Using a mmuno infrared sensor, they were able to identify the 68 subjects who later developed Alzheimer’s disease with high test accuracy.
The researchers looked at other biomarkers with the SIMOA technology, especially the P-tau181 biomarker, which is currently being proposed in several studies as a promising biomarker candidate.
“Unlike the clinical phase, however, this marker is not suitable for the early symptom-free phase of Alzheimer’s disease,” says Professor Klaus Gerwert in a summary of the results of the comparative study.
“Surprisingly, we found that the concentration of glial fiber protein (GFAP) can indicate disease up to 17 years before the clinical stage, although it does so much less precisely than the immuno-infrared sensor.”
In addition, by combining amyloid beta misfolding and GFAP concentration, the researchers were able to further increase the reliability of the test in the symptom-free stage.